[
    [
        {
            "time": "2020-03-15",
            "original_text": "复星医药与BioNTech启动新冠疫苗战略合作",
            "features": {
                "keywords": [
                    "复星医药",
                    "BioNTech",
                    "新冠疫苗",
                    "战略合作"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药与BioNTech启动新冠疫苗战略合作",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-03-16",
            "original_text": "多家公司因涉嫌信披违法违规遭证监会立案调查",
            "features": {
                "keywords": [
                    "立案调查",
                    "信披违规",
                    "证监会"
                ],
                "sentiment_score": -0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "多家公司因涉嫌信披违法违规遭证监会立案调查",
                "Correlation": 5,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-04",
            "original_text": "复星新冠mRNA疫苗4月底开展临床",
            "features": {
                "keywords": [
                    "复星医药",
                    "mRNA疫苗",
                    "临床试验"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星新冠mRNA疫苗4月底开展临床",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-03-15",
            "original_text": "复星医药附属与BioNTech签署疫苗产品许可协议，拟5000万美元认购其0.7%股权",
            "features": {
                "keywords": [
                    "复星医药",
                    "BioNTech",
                    "许可协议",
                    "股权投资"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药附属与BioNTech签署疫苗产品许可协议，拟5000万美元认购其0.7%股权",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-03-16",
            "original_text": "涨停板早知道：七大利好有望发酵",
            "features": {
                "keywords": [
                    "涨停板",
                    "利好",
                    "发酵"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "涨停板早知道：七大利好有望发酵",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        }
    ]
]